Novel PDGFβR antisense encapsulated in polymeric nanospheres for the treatment of restenosis

Gene Therapy

Volumn 9, Issue 23, 2002, Pages 1607-1616

  Cohen Sacks, H ^a   Najajreh, Y ^a,b   Tchaikovski, V ^c   Gao, G ^a   Elazer, V ^a   Dahan, R ^a   Gati, I ^a   Kanaan, M ^b   Waltenberger, J ^c   Golomb, G ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BETHLEHEM UNIVERSITY   (Israel)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Antisense oligonucleotides; Gene therapy; Local drug delivery; Restenosis; Slow release formulation; Smooth muscle cells

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; NANOPARTICLE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLYGLACTIN; POLYGLUTAMIC ACID; POLYMER; ANTISENSE OLIGONUCLEOTIDE; BIOMATERIAL; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOCOMPATIBILITY; BIODEGRADABILITY; CELL TRANSPORT; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENCAPSULATION; GENE DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INTIMA; NONHUMAN; PRIORITY JOURNAL; RAT; RESTENOSIS; REVIEW; ANIMAL; ARTICLE; BALLOON DILATATION; CAROTID ARTERY OBSTRUCTION; CELL DIVISION; CONFOCAL MICROSCOPY; CULTURE TECHNIQUE; DELAYED RELEASE FORMULATION; FEMALE; GENE THERAPY; GENE TRANSFER; GENETICS; MALE; METHODOLOGY; PATHOLOGY; RECURRENT DISEASE; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALIA;

ANIMALS; BALLOON DILATATION; BIOCOMPATIBLE MATERIALS; CAROTID STENOSIS; CELL CULTURE TECHNIQUES; CELL DIVISION; DELAYED-ACTION PREPARATIONS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; MALE; MICROSCOPY, CONFOCAL; MICROSPHERES; MUSCLE, SMOOTH, VASCULAR; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECURRENCE; TUNICA INTIMA;

EID: 18744410917     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301830     Document Type: Review

References (36)

1. Deshpande D, Rojanasakul Y. Antisense oligonucleotide therapeutics: a class of its own. Pharma News 1996; 3: 15-18.
2. Stein CA. The experimental use of antisense oligonucleotides: a guide for the perplexed. J Clin Invest 2001; 108: 641-644.
3. Akhtar S, Juliano RJ. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol 1992; 2: 139-144.
4. Mahato RI, Takakura Y, Hashida M. Development of targeted delivery systems for nucleic acid drugs. J Drug Target 1997; 4: 337-357.
5. Cohen H et al. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Therapy 2000; 7: 1896-1905.
6. Ledley FD. Pharmaceutical approach to somatic gene therapy. Pharm Res 1996; 13: 1595-1614.
7. Jong YS et al. Controlled release of plasmid DNA. J Control Rel 1997; 47: 123-134.
8. Labhasetwar VA et al. DNA controlled-release coating for gene transfer: transfection in skeletal and cardiac muscle. J Pharm Sci 1998; 87: 1347-1350.
9. Leong KW et al. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Rel 1998; 53: 183-193.
10. Chorny M, Fishbein I, Golomb G. Drug delivery systems for the treatment of restenosis. Crit Rev Ther Drug Carrier Syst 2000; 17: 249-284.
11. Waltenberger J. Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation 1997; 96: 4083-4094.
12. Fishbein I et al. Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats. Arterioscler Thromb Vasc Biol 2000; 20: 667-676.
13. Fishbein I et al. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J Control Rel 2000; 65: 221-229.
14. Hughes AD, Clunn GF, Refson J, Demoliou-Mason C. Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. Gen Pharmac 1996; 27: 1079-1089.
15. Noiseux N, Boucher CH, Cartier R, Sirosis MG. Bolus endovascular PDGFR-b antisense treatment suppressed intimal hyperplasia in a rat carotid injury model. Circulation 2000; 102: 1330-1336.
16. Sirois MG, Simons M, Edelman ER. Antisense oligonucleotide inhibition of PDGFR-b receptor subunit expression direct supression of intimal thickening. Circulation 1997; 95: 669-676.
17. Banai S et al. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 1998; 97: 1960-1969.
18. Waltenberger J et al. Ischemia-induced transplant arteriosclerosis in the rat. Induction of peptide growth factor expression. Arterioscler Thromb Vasc Biol 1996; 16: 1516-1523.
19. Waltenberger J et al. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Circ Res 1999; 85: 12-22.
20. Villa AE et al. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res 1995; 76: 505-513.
21. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plamid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J Pharm Sci 1999; 88: 126-130.
22. Liversidge GG, Phillips CP, Cundy KC. Method to reduce particle size growth during lyophilization. United States Patent. Sterling Winthrop, New York, NY, USA, 1994.
23. Cleek RL et al. Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles. J Biomed Mat Res 1997; 35: 525-530.
24. Abe J et al. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem Biophys Res Commun 1994; 198: 16-24.
25. Bennett MR et al. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994; 93: 820-828.
26. Edelman ER, Simons M, Sirois MG, Rosenberg RD. C-myc in vasculoproliferative disease. Circ Res 1995; 76: 176-182.
27. Simons M et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70.
28. Fishbein I et al. Drug delivery systems for the treatment of restenosis. In: Wise DI (ed.). Biomaterials and Bioengineering Handbook. Marcel Dekker: New York, 2000, pp 313-335.
29. Leppanen O et al. Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 2000; 20: E89-E95.
30. Langer R. New methods of drug delivery. Science 1990; 249: 1527-1533.
31. Juliano RL et al. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm Res 1999; 16: 494-502.
32. Rockwell P et al. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 1997; 94: 6523-6528.
33. Stein CA et al. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 1993; 32: 4855-4861.
34. Weinstein R et al. Fibronectin dependence for attachment in vitro: smooth muscle versus fibroblast. In: Sato GH, Pardee AB, Sirbasku DA (eds). Growth of Cells in Hormonally Defined Media. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1982, pp 145-154.
35. Yamada KM, Kennedy DW, Hayashi M. Fibronectin in cell adhesion, differentiation, and growth. In: Sato GH, Pardee AB, Sirbasku DA (eds). Growth of Cells in Hormonally Defined Media. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1982, pp 131-143.
36. Golomb G et al. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis 1996; 125: 171-182.